May 9th 2024
The program allows participants to reserve doses and be eligible for priority shipping, among other benefits.
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
Clinical ShowCase™: Finding the Best Path Forward for Patients with COPD
View More
Surv.AI Says™: What Clinicians and Patients Are Saying About Glucose Management in the Technology Age
View More
A Tethered Approach to Type 2 Diabetes Care – Connecting Insulin Regimens with Digital Technology
View More
FDA issues EUA for bamlanivimab and etesevimab to treat COVID-19
February 11th 2021The US Food and Drug Administration (FDA) issued an emergency use authorization (EUA) of monoclonal antibodies bamlanivimab and etesevimab to treat mild coronavirus disease 2019 (COVID-19) in both pediatric and adult patients.
Treating MIS-C with intravenous immunoglobulins and methylprednisolone to improve fever course
February 3rd 2021Does using methylprednisolone along with intravenous immunoglobulins improve fever outcomes for multisystem inflammatory syndrome in children (MIS-C) cases? A French investigation offers some answers.
How states addressed issues of equity when schools reopened
December 16th 2020One of the chief concerns with schools being closed was how it would impact children who need certain services or lacked access to basic needs such as food and shelter. A study looks into how state-level guidance addressed these concerns when schools reopened in the fall.